Investigational drug · Phase 2
SAR446268
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myotonic Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SAR446268"
First trial start
2025
Jul 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR446268", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myotonic Dystrophy
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR446268" as an intervention, largest first.
SanofiSanofi (SNY)
NCT06844214 · 32 participants (planned) · Start Jul 23, 2025 · Primary completion Feb 28, 2029
Drug: SAR446268 · For: Myotonic Dystrophy
Sites: Gainesville, Florida; Tampa, Florida; New York, New York · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development of an AAV-delivered microRNA gene therapy for myotonic dystrophy type 1.
Tomassy GS, Fan W, Cao S, et al. · Mol Ther 2025
Also in development for Myotonic Dystrophy
- Del-desiranAOC 1001Phase 33 trials
Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1
- Mexiletine granules for prolonged-releasePhase 32 trials
Lupin Ltd. · Myotonic Dystrophy
- zeleciment basivarsenDYNE-101Phase 32 trials
Dyne Therapeutics · Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.